Credit Suisse Reiterates Outperform on Intellia Therapeutics, Maintains $76 Price Target
Portfolio Pulse from richadhand@benzinga.com
Credit Suisse analyst Richard Law reiterated an Outperform rating on Intellia Therapeutics (NASDAQ:NTLA) and maintained a $76 price target.
June 13, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Credit Suisse analyst Richard Law reiterated an Outperform rating on Intellia Therapeutics and maintained a $76 price target.
The reiteration of the Outperform rating and maintenance of the $76 price target by Credit Suisse analyst Richard Law indicates a positive outlook for Intellia Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100